1. Home
  2. SRL vs ALDX Comparison

SRL vs ALDX Comparison

Compare SRL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

HOLD

Current Price

$6.13

Market Cap

96.5M

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

101.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRL
ALDX
Founded
2017
2004
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.5M
101.1M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
SRL
ALDX
Price
$6.13
$1.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
12.8K
891.7K
Earning Date
05-12-2026
05-01-2026
Dividend Yield
16.07%
N/A
EPS Growth
N/A
40.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$1.07
52 Week High
$10.39
$6.18

Technical Indicators

Market Signals
Indicator
SRL
ALDX
Relative Strength Index (RSI) 28.74 36.50
Support Level $5.37 $1.48
Resistance Level $6.44 $1.88
Average True Range (ATR) 0.35 0.09
MACD -0.02 0.02
Stochastic Oscillator 48.57 12.68

Price Performance

Historical Comparison
SRL
ALDX

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: